Cancer Drug Pipeline Information for Patient Advocacy Groups. Breast Cancer. Route of Administration. Brand Name Generic Name Manufacturer Indication

Transcription

1 Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the will be submitted to the pcodr program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that this information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document. Breast Cancer Brand Name Generic Name Manufacturer Indication Masivet masitinib AB Science Masivet masitinib AB Science Relapsed metastatic triple negative breast cancer Realpsed metastatic non-triple negative breast cancer veliparib AbbVie BRCA-deficient breast cancer veliparib AbbVie Xgeva denosumab Amgen Neoadjuvant treatment of triple negative breast cancer Prevention of bone metastases in patients with adjuvant breast cancer Xtandi enzalutamide Astellas Breast cancer Abraxane paclitaxel Celgene First-line metastatic triple-negative breast cancer CC-486 Celgene Metastatic breast cancer Halaven eribulin Eisai First/second-line HER2-negative breast cancer Subcutaneous Avastin bevacizumab Genentech Adjuvant breast cancer, HER2-negative e/ df/4q2015_rd_en.pdf ads/product-pipeline.pdf ads/product-pipeline.pdf peline.pdf Canadian Cancer Action Network

2 Avastin bevacizumab Genentech Adjuvant breast cancer, HER2-postive Kadcyla + Perjeta Kadcyla + Perjeta ipatasertib Genentech Triple-negative breast cancer SERD (GDC- 0810) trastuzumab- DM1 taselib RG6046 Genentech ER+ HER2-ngeative breast cancer Early HER2-positive breast cancer adjuvant HER2-negative, hormone receptor-positive metastatic breast cancer Metastatic ER-positive/HER2-negative breast cancer cobimetinib triple-negative breast cancer RG1273 pertuzumab RG3502 trastuzumab emtansine + pertuzumab RG3502 trastuzumab emtansine + pertuzumab RG7446 2nd line HER2-positive breast cancer early HER2-positive breast cancer, adjuvant treatment early HER2-positive breast cancer, neoadjuvant treatment metastatic triple-negative breast cancer, first-line treatment Canadian Cancer Action Network

3 Perjeta RG1273 pertuzumab buparlisib buparlisib ribociclib early HER2-positive breast cancer Novartis Novartis Novartis Metastatic breast cancer, hormone receptorpositive, aromatese inhibitor and mtor inhibitor resistant naive Metastatic breast cancer, hormone receptorpositive, aromatese inhibitor and mtor inhibitor resistant solid tumours HR+ HER2- advanced breast cancer in pre and postmenopausal women Ibrance palbociclib Pfizer Recurrent advanced breast cancer Ibrance palbociclib Pfizer High-risk early breast cancer PF Pfizer Triple-negative breast cancer Ibrance palbociclib Pfizer SAR (MM121) Postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease Sanofi Breast cancer ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf s/productpipeline/042815_pipeline_update_fin al.pdf s/productpipeline/042815_pipeline_update_fin al.pdf s/productpipeline/042815_pipeline_update_fin al.pdf OnDrugs/ApprovedDrugs/ucm ne/default.aspx Canadian Cancer Action Network

4 MLN0128 Takeda Breast cancer pipeline_ _en.pdf Canadian Cancer Action Network

5 Endocrine Cancer Lenvima lenvatinib Eisai Avastin bevacizumab Genentech High-risk carcinoid Zelboraf vemurafenib Genentech Locally recurrent or metastatic, progressive, radioactive ioidine-refractory differentiated thyroid cancer Papillary thyroid cancer, BRAF mutation positive OnDrugs/ApprovedDrugs/ucm Canadian Cancer Action Network

6 Gastrointestinal Cancer Masivet masitinib AB Science Relapsed metastatic colorectal cancer Masivet masitinib AB Science Pancreatic cancer Masivet masitinib AB Science Relapsed metastatic liver cancer Masivet masitinib AB Science Relapsed gastric cancer Masivet masitinib AB Science Masivet masitinib AB Science AMG 337 Amgen Gastric cancer Iclusig ponatinib Ariad Gastrointestinal stromal tumour, first-line treatment Gastrointestinal stromal tumour, secondline treatment Metastatic and/or unresectable gastrointestinal stromal tumors Xtandi enzalutamide Astellas Hepatocellular carcinoma Vargatef nintedanib Boehringer Ingelheim Colorectal cancer paclitaxel Celgene Adjuvant therapy for pancreatic cancer Lenvima lenvatinib Eisai Hepatocellular carcinoma MORAb-004 Eisai Colorectal cancer E7820 Eisai Colorectal cancer Cyramza ramucirumab Eli Lilly Second-line colorectal cancer e/ df/4q2015_rd_en.pdf /drug_discovery/pipeline.l ads/product-pipeline.pdf peline.pdf peline.pdf peline.pdf uments/pipeline/clinical%20develop ment%20pipeline/index.l Canadian Cancer Action Network

7 Cyramza ramucirumab Eli Lilly First-line gastric cancer Cyramza ramucirumab Eli Lilly Metastatic colorectal cancer, in combination with Folfiri, for patients whose disease has progressed on a first line bevacizumab, oxaliplatin, and fluoropyrimidine-containing regimen evofosfamide EMD Serono Pancreatic cancer Cometriq cabozantinib Exelixis ipatasertib Genentech Gastric cancer Metestatic renal cell carcinoma who have experienced disease progression following treatment with at least one ptiot VEGFR kinese inhibitor onartuzumab Genentech Metastatic colorectal cancer onartuzumab Genentech Metastatic HER2-negative gastric cancer Perjeta pertuzumab Genentech HER2-positive gastric cancer GS-5745 Gilead Gastric cancer Zydelig momelotinib Gilead Pancreatic cancer Mekinist Tafinlar panitumumab trametinib dabrafenib panitumumab trastuzumab- DM1 Novartis Colorectal cancer Advanced HER2-positive gastric cancer & uments/pipeline/clinical%20develop ment%20pipeline/index.l OnDrugs/ApprovedDrugs/ucm ch/pipeline/research.l ne ne ovartis.com/files/ meet-themanagement-2-pharma.pdf Canadian Cancer Action Network

8 Perjeta vanucizumab RG7686 RG1273 pertuzumab Somatuline lanreotide Ipsen Pharma Colorectal cancer Metastatic liver cancer advanced HER2-positive gastric cancer Unresectable, well or moderately differentiated, locally, advanced or metastatic gastroenteropancreatic neuroendocrine tumors Subcutaneous Keytruda pembrolizumab Merck Gastric cancer MLN0264 Takeda Gastric cancer MLN0264 Takeda Pancreatic cancer OnDrugs/ApprovedDrugs/ucm ne/home.l pipeline_ _en.pdf pipeline_ _en.pdf Canadian Cancer Action Network

9 Genitourinary Cancer Masivet masitinib AB Science Xtandi enzalutamide Astellas Metastatic castrate-resistent prostate cancer, first-line treament Non-metastatic castration-resistant prostate cancer Prostate cancer in patients with nonmetastatic biochemical recurrence df/4q2015_rd_en.pdf Cyramza ramucirumab Eli Lilly Second-line bladder cancer uments/pipeline/clinical%20develop ment%20pipeline/index.l Cometriq cabozantinib Exelixis Metastatic renal cell cancer ipatasertib Genentech Prostate cancer Votrient pazopanib Novartis Adjuvant therapy for renal cell cancer RG7446 RG7446 RG7446 RG7599 lifastuzumab vedotin RG7446 Second-line urothelial bladder cancer Metastatic urothelial bladder cancer Renal cell cancer, in combination with Avastin platinum-resistant ovarian cancer muscle-invasive bladder cancer, adjuvant treatment Canadian Cancer Action Network

10 Zytiga abiraterone acetate Janssen Non-metastatic castration-resistant prostate cancer Keytruda pembrolizumab Merck Bladder cancer Inlyta axitinib Pfizer Renal cell carcinoma adjuvant, in combination with Keytruda Sutent sunitinib Pfizer Renal cell carcinoma adjuvant Jevtana cabazitaxel Sanofi Metastatic prostate cancer (1L) TAK-385 Takeda Prostate cancer s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf ne/home.l s/productpipeline/042815_pipeline_update_fin al.pdf s/productpipeline/042815_pipeline_update_fin al.pdf peline/default.aspx pipeline_ _en.pdf Canadian Cancer Action Network

11 Gynecological Cancer Lynparza olaparib AstraZeneca Monotherapy for deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer for patients who have been treated with three or more prior lines of chemotherapy Lenvima lenvatinib Eisai Endometrial cancer farletuzumab Eisai Platinum-sensitive ovarian cancer Avastin bevacizumab Genentech First-line metastatic ovarian cancer lifastuzumab vedotin Genentech & Platinum-resistent ovarian cancer afuresertib Novartis Ovarian cancer Avastin bevacizumab Relapsed platinum-sensitive ovarian cancer Avastin RG435 bevacizumab 1st line metastatic ovarian cancer binimetinib Novartis Low-grade serious ovarian cancer SAR with MSC B Sanofi dual inhibitor of PI3K & mtor, pimasertib OnDrugs/ApprovedDrugs/ucm peline.pdf peline.pdf professionals/pipeline duct-pipeline-2014.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf peline/default.aspx Canadian Cancer Action Network

12 Head and Neck Cancer Masivet masitinib AB Science Relapsed metastatic head and neck cancer MEDI4736 AstraZeneca Nimoral nimorazole Azanta Nimoral nimorazole Azanta Giotrif afatinib Boehringer Ingelheim Second-line PD-L1 positive metastatic head and neck squamous cell carcinoma First-line head and neck squamous cell carcinoma, versus accelerated chemoradiation therapy First-line platinum-resistent head and neck squamous cell carcinoma, versus conventional radiation therapy Head and neck squamous cell carcinoma CC-486 Celgene Advanced nasopharyngeal cancer Keytruda pembrolizumab Merck Head and neck cancer h/our-pipeline-summary /drug_discovery/pipeline.l ads/product-pipeline.pdf ne/home.l Canadian Cancer Action Network

13 Leukemia Blincyto blinatumomab Amgen Blincyto blinatumomab Amgen Relapsed/refractory acute lymphoblastic leukemia Relapsed/refractory Philadelphia chromosone-positive (Ph+) and minimal residual disease of acute lymphoblastic leukemia ASP2215 Astellas Acute myeloid leukemia volasertib Boehringer Ingelheim Acute myeloid leukemia Revlimid lenalidomide Celgene Second-line chronic lymphocitic leukemia Vidaza azacitidine Celgene Post-induction acute myeloid leukemia maintenance Promacta eltrombopag Novartis Acute myeloid leukemia Azerra ofatumumab Novartis venetoclax venetoclax venetoclax Chronic lymphocytic leukemia, use in relapsed patients Frontline chronic lymphocytic leukemia, in combination with Gazyva Realpsed/refractory chronic lymphocytic leukemia, in combination with rituximab Relapsed/refractory chronic lymphocytic leukemia 17p deletion e/ e/ df/4q2015_rd_en.pdf /drug_discovery/pipeline.l ds/product-pipeline.pdf ads/product-pipeline.pdf duct-pipeline-2015.pdf Canadian Cancer Action Network

14 Imbruvica ibrutinib Janssen Imbruvica ibrutinib Janssen Purixan mercaptopurine NOVA Labratories midostaurin Novartis Tasigna nilotinib Novartis inotuzumab ozogamicin Pfizer Treatment naive patients with chronic lymphocytic leukemia (single agent) Frontline chronic lymphocytic leukemia, in combination with obinutuzumab Acute lymphoblastic leukemia, as part of a combination regime Acute myeloid leukemia, aggressive systemic mastocytosis Chronic myeloid leukemia treatment-free remission Acute lymphoblastic leukemia glasdegib Pfizer Acute myeloid leukemia Bosulif bosutinib Pfizer glasdegib (PF )SMO (smoothened) Pfizer Adult patients with newly diagnosed chronic phase chronic myelogenous leukemia, versus imatinib antagonist Acute Myeloid Leukemia, *Cancer s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf OnDrugs/ApprovedDrugs/ucm ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf s/productpipeline/042815_pipeline_update_fin al.pdf s/productpipeline/042815_pipeline_update_fin al.pdf s/productpipeline/042815_pipeline_update_fin al.pdf e_and_technology/product_pipeline Canadian Cancer Action Network

15 SAR3419/Mayta nsine-loaded anti-cd19 monoclonal antibody Sanofi Acute lymphoblastic leukemia, Non- Hodgkin's lymphoma ne/default.aspx Canadian Cancer Action Network

16 Lung Cancer gefitinib (IRESSA) Masivet masitinib AB Science For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Relapsed metastatic non-small cell lung cancer veliparib AbbVie Non-small cell lung cancer Xgeva denosumab Amgen Non-small cell lung cancer Subcutaneous brigatinib Ariad Tarceva erlotinib Astellas AZD9291 MEDI4736 AZD9291 MEDI4736 AstraZeneca AstraZeneca AstraZeneca AstraZeneca Locally advanced or metastatic non-small cell lung cancer First-line treatment of metastatic non-small cell lung cancer patients whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations First-line EGFR-mutated non-small cell lung cancer, versus a standard of care EGFR-TKI (gefitinib and erlotinib) Third-line PD-L1 positive metastatic nonsmall cell lung cancer Patients with advanced EGFR-mutated nonsmall cell lung cancer who also have the T790M resistance mutation after the failure of standard first-line anti-egfr treatment Locally-advanced unresectable non-small cell lung cancer OnDrugs/ApprovedDrugs/ucm e/ OnDrugs/ApprovedDrugs/ucm h/our-pipeline-summary h/our-pipeline-summary h/our-pipeline-summary h/our-pipeline-summary Canadian Cancer Action Network

17 Giotrif Vargatef Opdivo MEDI4736 AstraZeneca Adjuvant non-small cell lung cancer MEDI4736 afatinib BI nintedanib nivolumab AstraZeneca Boehringer Ingelheim Boehringer Ingelheim Boehringer Ingelheim Bristol-Myers Squibb Third-line metastatic non-small cell lung cancer Contains a monotherapy sub-study for PD- L1 positive patients lung squamous cell carcinoma Nonsquamous non-small cell lung cancer Non-small cell lung cancer Metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy CC-486 Celgene Advanced non-small cell lung cancer Halaven eribulin Eisai Non-small cell lung cancer Lenvima lenvatinib Eisai Lenvima lenvatinib Eisai Third-line monotherapy for non-small cell lung cancer Non-small cell lung cancer (RET translocations) farletuzumab Eisai Non-small cell lung cancer necitumumab Eli Lilly Squamous non-small cell lung cancer h/our-pipeline-summary h/our-pipeline-summary /drug_discovery/pipeline.l /drug_discovery/pipeline.l /drug_discovery/pipeline.l OnDrugs/ApprovedDrugs/ucm ads/product-pipeline.pdf peline.pdf peline.pdf peline.pdf peline.pdf uments/pipeline/clinical%20develop ment%20pipeline/index.l Canadian Cancer Action Network

18 Cyramza ramucirumab Eli Lilly Metastatic non-small cell lung cancer with disease progression on or after platinumbased chemotherapy, in combination with docetaxel evofosfamide EMD Serono Non-small cell lung cancer Tepotinib1 c EMD Serono Non-small cell lung cancermet kinase inhibitor Non-small cell lung cancer Avelumab EMD Serono Anti-PD-L1 mab Non-small cell lung cancer Avastin bevacizumab Genentech Adjuvant non-small cell lung cancer Tarceva erlotinib Genentech Mekinist Tafinlar Kadcyla trametinib dabrafenib RG7446 RG7446 RG7446 alectinib trastuzumab emtansine First-line metastatic non-small cell lung cancer, EGFR mutation positive Novartis Non-small cell lung cancer First-line non-squamous non-small cell lung cancer, PDL1-selected patients Second-line non-small cell lung cancer First-line non-squamous non-small cell lung cancer, in combination with chemotherapy, with or without Avastin ALK-postiive non-small cell lung cancer, first-line treatment HER2-positive advanced non-small cell lung cancer OnDrugs/ApprovedDrugs/ucm ch/pipeline/research.l ch/pipeline/research.l ch/pipeline/research.l Added duct-pipeline-2015.pdf Canadian Cancer Action Network

19 Avastin bevacizumab RG7446 taselisib RG7853 RG7446 RG7446 RG7446 RG chemo + Avastin EGFR-mutation positive non-small cell lung cancer Metastatic non-small cell lung cancer Squamous non-small cell lung cancer ALK-positive, non-small cell lung cancer, second-line treatment First-line squamous non-small cell lung cancer, PDL1-selected patients First-line squamous non-small cell lung cancer non-small cell lung cancer, adjuvant treatment, PDL1-selected patients first-line non-squamous non-small cell lung cancer Keytruda pembrolizumab Merck Non-small cell lung cancer capmatinib Novartis Non-small cell lung cancer avelumab Pfizer Second-line non-small cell lung cancer ne/home.l ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf s/productpipeline/042815_pipeline_update_fin al.pdf Canadian Cancer Action Network

20 dacomitinib Pfizer First-line, EGFR-mutant non-small cell lung cancer alisertib Takeda Small cell lung cancer s/productpipeline/042815_pipeline_update_fin al.pdf pipeline_ _en.pdf Canadian Cancer Action Network

21 Lymphoma and Myeloma brentuximab vedotin (ADCETRIS) For the post-autologous hematopoietic stem cell transplantation (auto-hsct) consolidation treatment of patients with classical Hodgkin lymphoma (HL) at high risk of relapse or progression. Masivet masitinib AB Science Relapsed multiple myeloma Masivet masitinib AB Science Relapsed peripheral T-cell lymphoma Elotuzumab AbbVie Multiple myeloma Blincyto blinatumomab Amgen Diffuse large B-cell lymphoma Kyprolis carfilzomib Amgen Xgeva denosumab Amgen Newly diagnosed multipe myeloma, in combination with melphalan and prednisone, compared to bortezomib, melphalan, and prednisone Prevention of skeletal-related events in patients with multiple myeloma Revlimid lenalidomide Celgene Diffuse large B-cell lymphoma maintenance Revlimid lenalidomide Celgene First-line diffuse large B-cell lymphoma (ABC-subtype) Revlimid lenalidomide Celgene Relapsed/refractory indolent lymphoma Revlimid lenalidomide Celgene First-line follicular lymphoma Subcutaneous Istodax romidepsin Celgene First-line peripheral T-cell lymphoma OnDrugs/ApprovedDrugs/ucm e/ e/ e/ ds/product-pipeline.pdf ds/product-pipeline.pdf ads/product-pipeline.pdf ads/product-pipeline.pdf ads/product-pipeline.pdf Canadian Cancer Action Network

22 Revlimid lenalidomide Celgene Mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomid abemaciclib Eli Lilly Mantle cell lymphoma Gazyva obinutuzumab Genentech Diffuse large B-cell lymphoma Gazyva obinutuzumab Genentech Gazyva obinutuzumab Genentech polatuzumab vedotin Genentech Zydelig idelalisib Gilead Front-line indolent non-hodgkin's lymphoma Refractory indolent non-hodgkin's lymphoma Non-Hodgkin's lymphoma and diffuse large B-cell lymphoma Relapsed refractory indolent non-hodgkin's lymphoma Zydelig momelotinib Gilead Frontline indolent non-hodgkin's lymphoma Azerra ofatumumab Novartis Follicular lymphoma relapsed after rituximab-containing therapy Gazyva obinutuzumab Diffuse large B-cell lymphoma Gazyva obinutuzumab Rituxumab-refractory indolent non- Hodgkin's lymphoma venetoclax Front-line diffuse large B-cell lymphoma venetoclax Relapsed/refractory follicular lymphoma, in combination with rituximab OnDrugs/ApprovedDrugs/ucm uments/pipeline/clinical%20develop ment%20pipeline/index.l ne ne duct-pipeline-2015.pdf Canadian Cancer Action Network

23 Gazyva RG7159 obinutuzumab daratumumab daratumumab daratumumab daratumumab front-line indolent non-hodgkin's lymphoma Janssen Janssen Janssen Janssen Imbruvica ibrutinib Janssen Imbruvica ibrutinib Janssen Imbruvica ibrutinib Janssen Farydak panobinostat Novartis Relapsed/refractory multiple myeloma, in combination with lenalidomide/dexamethasone Relapsed/refractory multiple myeloma, in combination with bortezomib/dexamethasone Frontline multiple myeloma transplantineligible patients, in combination with bortezomib, melphalan and prednisone Frontline multiple myeloma transplantineligible patients, in combination with lenalidomide and low-dose dexamethasone Treatment naive patients with mantle cell lymphoma, in combination with Bendamustine and Rituximab Relapsed/refractory indolent nn-hodgkin's lymphoma, in combination with bendamustine and rituximab or R-CHOP Newly diagnosed non-germinal centre B- cell subtype of diffuse large B-cell lymphoma, in combination with R-CHOP Relapsed or relapsed-and-refractory multiple myeloma s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf Canadian Cancer Action Network

24 Farydak panobinostat Novartis Multiple myeloma, in combination with bortezomib and dexamethasone, for patients who have received at least two prior regimens including bortezomib and an immunomodulatory agent Afinitor everolimus Novartis Diffuse large C-cell lymphoma Imbruvica ibrutinib Pharmacyclics Adcetris Adcetris Adcetris Adcetris Adcetris SAR Sanofi Multiple myeloma brentuximab vedotin brentuximab vedotin brentuximab vedotin brentuximab vedotin brentuximab vedotin Seattle Genetics Seattle Genetics Seattle Genetics Seattle Genetics Seattle Genetics Patients with mantle cell lymphoma who have received at least one prior therapy Frontline treatment of advanced classical Hodgkin lymphoma, plus AVD, versus ABVD Frontline treatment for mature T-cell lymphoma, in combination with CHP, versus the standard-of-care CHOP Relapsed CD30-positive cutaneous T-cell lymphoma (primary cutaneous anaplastic large cell lymphoma, mycosis fungiodes), versus investigator's choice of methrotrexate or bexarotene Patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant Frontline treatment of diffuse large B-cell lymphoma in combination with RCHOP or RHCP OnDrugs/ApprovedDrugs/ucm ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf OnDrugs/ApprovedDrugs/ucm D_Portfolio_Phase_II-I_ pdf _trials _trials _trials _trials _trials Canadian Cancer Action Network

25 Adcetris brentuximab vedotin Seattle Genetics Beleodaq belinostat Spectrum Frontline treatment of Hodgkin lymphoma in patients age 60+, as a single agent and in combination with other agents Relapsed or refractory peripheral T-cell lymphoma ixazomib Takeda Previously untreated multiple myeloma ixazomib Takeda Relapsed or refractory multiple myeloma ixazomib ixazomib Takeda Takeda Velcade bortezomib Takeda Maintenance therapy in patients with newly diagnosed multiple myeloma following autologous stem cell transplant Maintenance therapy in patients with newly diagnosed multiple myeloma not treated with stem cell transplant Frontline treatment of mantle cell lymphoma _trials OnDrugs/ApprovedDrugs/ucm pipeline_ _en.pdf pipeline_ _en.pdf pipeline_ _en.pdf pipeline_ _en.pdf pipeline_ _en.pdf Canadian Cancer Action Network

26 Melanoma Masivet masitinib AB Science Metastatic melanoma with JM mutation of c- KIT Masivet masitinib AB Science Relapsed metastatic melanoma Opdivo talimogene laherparepvec nivolumab Amgen Bristol-Myers Squibb Regionally or distantly metastatic melanoma Unresectable or metastatic melanoma and disease progression following ipilimumab and a BRAF inhibitor if BRAF V600 mutation positive Lenvima lenvatinib Eisai Melanoma Ontak Mekinist Tafinlar MORAb-004 Eisai Melanoma denileukin diftitox Eisai Melanoma pimasertib EMD Serono Melanoma evofosfamide EMD Serono Melanoma cobimetinib trametinib dabrafenib cobimetinib Exelixis Unresectable locally advanced or metastatic melanoma harbouring a BRAF V600 mutation, in combination with vemurafenib Novartis Metastatic melanoma, adjuvant therapy Zelboraf vemurafenib Metastatic melanoma - BRAF mutation positive, in combination with Zelboraf Adjuvant melanoma, BRAF mutation positive e/ OnDrugs/ApprovedDrugs/ucm peline.pdf peline.pdf peline.pdf ch/pipeline/research.l ch/pipeline/research.l _0973_xl518 duct-pipeline-2015.pdf Canadian Cancer Action Network

27 binimetinib Novartis NRAS mutant melanoma binimetinib encorafenib Novartis RAF mutant melanoma ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf Canadian Cancer Action Network

28 Neurological Cancer Masivet masitinib AB Science Relapsed glioblastoma multiforme veliparib AbbVie Brain metastasis and other cancers Avastin bevacizumab Genentech First-line glioblastoma multiforme Unituxin dinutuximab United Therapeutics High-risk neuroblastoma in combination with GM-CSF, IL-2 and 13-cis-retinoic acid, for pediatric patients who have achieved at least a partial response to prior first-line multiagent, multimodality therapy OnDrugs/ApprovedDrugs/ucm Canadian Cancer Action Network

29 Sarcoma Halaven eribulin Eisai Sarcoma MORAb-004 Eisai Sarcoma evofosfamide EMD Serono Soft-tissue sarcoma Yondelis trabectedin Janssen Soft tissue sarcoma peline.pdf peline.pdf ch/pipeline/research.l s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf Canadian Cancer Action Network

30 Other Xgeva denosumab Amgen Adults and skeletally-mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to reult in severe morbidity oprozomib Amgen Hematologic malignancies Vectibix panitumumab Amgen ABP 215 ABP 494 ABP 798 ABP 980 Amgen Amgen Amgen Amgen Chemorefractory, wild-type KRAS exon 2 mcrc The same indications as bevacizumab - colorectal cancer, non-squamous nonsmall cell lung cancer, glioblastoma, renal cell carcinoma, breast cancer and ovarian cancer The same indications as cetuximab - colorectal cancer and head and neck cancer The same indications as rituximab - non- Hodgkin's lymphoma and chronic lymphocytic leukemia The same indications as trastuzumab - HER2+ breast cancer and HER2+ positive gastric cancer Revlimid lenalidomide Celgene Myelodysplastic syndrome - deletion 5q Revlimid lenalidomide Celgene Myelodysplastic syndrome - non-deletion 5q CC-486 Celgene Lower-risk myelodysplastic syndrome CC-486 Celgene Myelodysplastic syndrome - post hypomethylating agent failure Subcutaneous OnDrugs/ApprovedDrugs/ucm e/ e/ e/ e/ e/ e/ ds/product-pipeline.pdf ds/product-pipeline.pdf ads/product-pipeline.pdf ads/product-pipeline.pdf Canadian Cancer Action Network

31 sotatercept Celgene Myleodysplastic syndrome luspatercept Celgene Myleodysplastic syndrome Subcutaneous amatuximab Eisai Mesothelioma Tepotinib1 c EMD Serono Hepatocellular cancer polatuzumab vedotin Genentech & Hematological malignancies momelotinib Gilead Myelofibrosis entospletinib Gilead Hematological malignancies Promacta eltrombopag Novartis Myelodyspastic syndromes emactuzumab ipatasertib Imbruvica ibrutinib Janssen Solid tumours Solid tumours & pigmented villonodular synovitis Previously treated adults with Waldenstrom's macroglobulinemia, in combination with Rituximab ribociclib Novartis Solid tumours ads/product-pipeline.pdf ads/product-pipeline.pdf peline.pdf ch/pipeline/research.l Added ne ne s/jnj/ x0x674691/1423ebb e-9af6- c0b1c429da15/jnj_pipeline.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf Canadian Cancer Action Network

32 binimetinib Novartis Solid tumours EGF816 Novartis Solid tumours BGJ398 Novartis Solid tumours encorafenib Novartis Solid tumours sonidegib (Odomzo Capsules, Novartis Pharmaceutical s Corporation) Novartis Pharmaceuticals Corporation For the treatment of patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. avelumab Pfizer Metastatic merkel cell carcinoma Imbruvica ibrutinib Pharmacyclics Waldenstrom's macroglobulinemia ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf ovartis.com/files/novartis_pipeline_20 14AnnualReport_Pdf.pdf OnDrugs/ApprovedDrugs/ucm s/productpipeline/042815_pipeline_update_fin al.pdf OnDrugs/ApprovedDrugs/ucm Canadian Cancer Action Network